Thalidomide | ALZFORUM Thalidomide has been reintroduced and used for a number of immunological and inflammatory disorders, as well as multiple myeloma and other types of cancer Thalidomide displays anti-angiogenic and immunosuppressive activity It modulates various cytokines, including inhibiting release of tumor necrosis factor-alpha (TNFα) from monocytes
Lenalidomide - ALZFORUM Lenalidomide is structurally similar to thalidomide, and as such is considered a teratogen with the potential to cause birth defects and fetal death Lenalidomide is being pursued as an alternative to thalidomide, whose development for AD was stopped because of dose-limiting toxicity in elderly patients (Decourt et al , 2017)
Therapeutics - ALZFORUM AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total
New Arrows Aimed at Tau: Single-Domain Antibody, Peptibody, Vaccine When the scientists conjugated this sdAb to thalidomide to bind E3 ubiquitin ligase and trigger degradation of the complex, the treatment nearly eliminated aggregated α-synuclein Sigurdsson believes sdAbs have potential as both therapeutics and PET ligands, and has a paper coming out on the latter later this month Trim the Tau
International Conference on Alzheimers and Parkinsons . . . - ALZFORUM Queen Silvia of Sweden opened the 17th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 28 to April 1 in Sweden's southwestern city of Gothenburg The queen, age 79, flew in from Stockholm through a snowstorm, toured the labs of Kaj Blennow and Henrik Zetterberg at Sahlgrenska University Hospital, and then addressed the 3,000 in-person and 1,000 virtual